The trial will give the drug Trontinemab to those at high risk of Alzheimer’s to see if the disease can be delayed or prevented

The first participants in Europe will be screened in Britain from Monday, with more than 15 UK centres expected to take part in the global study.

Healthy middle-aged people deemed to be at higher risk of developing condition among those eligible to participate